Genmab A/S (GMAB)
After hours:
| Previous close | 38.37 |
| Open | 38.27 |
| Bid | 37.72 x 1300 |
| Ask | 38.73 x 800 |
| Day's range | 38.15 - 38.86 |
| 52-week range | 26.19 - 47.50 |
| Volume | |
| Avg. volume | 657,378 |
| Market cap | 25.237B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 30.13 |
| EPS (TTM) | 1.27 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.75 |
- GlobeNewswire
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well as the Company’s subsidiaries and 5,138 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted sto
- GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio
- Zacks
GILD or GMAB: Which Is the Better Value Stock Right Now?
GILD vs. GMAB: Which Stock Is the Better Value Option?
